Results 221 to 230 of about 50,819 (268)
Limited adoption of thymectomy for nonthymomatous myasthenia gravis. [PDF]
J Thorac DisCarrera D +4 more
europepmc +1 more source
Comment on "Postoperative Complications Following Spine Surgery in Myasthenia Gravis Patients: A Propensity-Matched National Database Analysis". [PDF]
Global Spine JXu Y, Zou J, Yang X.
europepmc +1 more source
Optimizing myasthenia gravis management in practice: integrating clinical scales and classification systems. [PDF]
Arq NeuropsiquiatrBaima JPS +6 more
europepmc +1 more source
Effect of CXCR5, PD-1 and ICOS on B-cell responses and relevance to myasthenia gravis. [PDF]
Clin Transl ImmunologyÇebi M +4 more
europepmc +1 more source
Prospective study of efgartigimod in severe myasthenia gravis exacerbations requiring ventilatory or enteral support. [PDF]
J Neuromuscul DisShelly S +5 more
europepmc +1 more source
Seminars in Neurology, 2015 Myasthenia gravis is an autoimmune neuromuscular disease caused by antibodies directed against the postsynaptic muscle membrane. The clinical hallmark of the disease is fluctuating and fatigable weakness that affects the ocular muscles (resulting in diplopia and ptosis), the bulbar muscles (causing dysphagia, dysarthria, and dyspnea), and extremity ...
Kelly G, Gwathmey, Ted M, Burns
core +4 more sources
JAAPAMyasthenia gravis (MG) is a rare neuromuscular junction disorder that is characterized by fatigable weakness of muscles. People with MG experience various clinical manifestations based on the muscles involved. MG can be autoimmune, paraneoplastic, congenital, medication-related, or transient in the neonatal period due to the passive placental transfer ...
Mamatha, Pasnoor +2 more
core +5 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Seminars in Neurology, 1990
The treatment of patients with myasthenia gravis should be individualized according to the extent (ocular versus generalized) and severity (mild to severe) of disease, the presence or absence of concomitant disease (including but not limited to other autoimmune diseases and thymoma), and, to a lesser degree, the age of the patient. Thymectomy should be
D M, Linton, D, Philcox
openaire +4 more sources
The treatment of patients with myasthenia gravis should be individualized according to the extent (ocular versus generalized) and severity (mild to severe) of disease, the presence or absence of concomitant disease (including but not limited to other autoimmune diseases and thymoma), and, to a lesser degree, the age of the patient. Thymectomy should be
D M, Linton, D, Philcox
openaire +4 more sources
New England Journal of Medicine, 2016
Myasthenia gravis is an autoimmune disease, which leads to load-dependent weakness of voluntary skeletal muscles with recovery of function after resting. The disease is caused by autoantibodies directed against the postsynaptic nicotinic acetylcholine receptors (AChR) leading to a reduction of neuromuscular transmission.
Sabina, Miranda +2 more
openaire +8 more sources
Myasthenia gravis is an autoimmune disease, which leads to load-dependent weakness of voluntary skeletal muscles with recovery of function after resting. The disease is caused by autoantibodies directed against the postsynaptic nicotinic acetylcholine receptors (AChR) leading to a reduction of neuromuscular transmission.
Sabina, Miranda +2 more
openaire +8 more sources